Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Andrew Leech

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Brendon Yee

Prof Brendon Yee

OSA – Which Test for Which Patient

Dr Sonia Davison

Dr Sonia Davison

Musculoskeletal Health in Menopause

Mr David Gardner

Mr David Gardner

AHPRA-Proof Your Practice – Social Media Risks for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023